Analysts Set Artivion, Inc. (NYSE:AORT) PT at $49.11

Shares of Artivion, Inc. (NYSE:AORT) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $49.1143.

Several equities analysts have recently commented on the stock. Canaccord Genuity Group restated a “buy” rating and set a $51.00 price target on shares of Artivion in a research report on Wednesday, December 17th. Citizens Jmp upped their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th.

Insiders Place Their Bets

In other news, insider John E. Davis sold 6,563 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total transaction of $300,979.18. Following the transaction, the insider directly owned 198,842 shares of the company’s stock, valued at approximately $9,118,894.12. This trade represents a 3.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the completion of the sale, the senior vice president directly owned 44,753 shares of the company’s stock, valued at $2,015,675.12. The trade was a 51.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 206,243 shares of company stock worth $9,351,134. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd lifted its position in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter worth $27,000. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares during the period. USA Financial Formulas boosted its stake in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after buying an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after buying an additional 538 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Up 0.1%

Shares of Artivion stock opened at $39.50 on Friday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -164.56 and a beta of 1.59. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50. The business’s 50 day simple moving average is $44.19 and its 200-day simple moving average is $42.66.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The business’s quarterly revenue was up 18.9% compared to the same quarter last year. Equities research analysts forecast that Artivion will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.